Bispecific antibodies targeting CD3 in oncology and hematology

xlomafota13 shared this article with you from Inoreader Bispecific antibodies targeting CD3 in oncology and hematology Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S181-S194. doi: 10.1016/j.bulcan.2021.06.003. ABSTRACT Bispecific therapies targeting CD3, so-called T-cell engagers (TCE), belong to the new spectrum of anti-tumor immunotherapies stimulating T-lymphocytes. TCE are unique constructs targeting the MHC-independent CD3 epsilon subunit (CD3e) and a tumor antigen. To date, only blinatumomab have reached market agreements in lymphoid malignancies with constructs targeting CD3exCD19. Other TCE are in advances development, with promising results targeting CD20 and BSMA in lymphoma and myeloma. These successes have relaunched the development of TCE in solid tumors, bringing mixed results so far (notably in terms of tolerance). Still, TCE pave the way to new immunotherapy in tumors considered to be refractory to inhibitors of immune checkpoints such as prostate cancer or colorectal cancer. PMID:34920802 | DOI:10.1016/j.bulcan.2021.06.003 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.